By THE ASSOCIATED PRESSOCT. 1, 2015
The first combination of drugs aimed at bolstering the immune system to fight cancer has been approved, giving the drug maker Bristol-Myers Squibb an early lead over competitors. The Food and Drug Administration gave accelerated approval to a regimen combining the drug maker’s approved immuno-oncology drugs, Opdivo and Yervoy, to treat the half of patients with advanced melanoma who have a genetic variation called “BRAF wild-type.” Together, the drugs slowed or temporarily stopped tumor progression in 60 percent of patients, versus 11 percent of those who received only Yervoy, in a pivotal study of 140 previously untreated patients with melanoma, the deadliest type of skin cancer. But with a wholesale price of $141,000 to $256,000, even insured patients may not be able to afford their portion of the bill. Bristol-Myers shares rose 86 cents to close at $60.03.A version of this brief appears in print on October 2, 2015, on Page B2 of the New York edition with the headline: Fda Approves Combining Two Cancer-Fighting Drugs .  Order Reprints| Today's Paper|Subscribe

We’re interested in your feedback on this page. Tell us what you think.